Regions

MasterControl launches Version 11.7

Monday, November 20, 2017

MasterControl, a global provider of software solutions that enable life science and other regulated companies to deliver life-improving products to more people sooner, has released MasterControl Version 11.7 that includes powerful new analytics capabilities as well as three new cloud-based solutions, MasterControl eTMF Manager, MasterControl Registrations and MasterControl Registrations for eCTD.

[Read More]

Fasenra receives FDA approval for severe eosinophilic asthma

Monday, November 20, 2017

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the FDA has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. FASENRA is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.

[Read More]

Science Exchange, Alector partner

Monday, November 20, 2017

Science Exchange, a secure enterprise platform and aggregator for outsourced research and development (R&D), announced a strategic partnership with Alector, a biotech company pioneering the discovery & development of immuno-neurology therapies for neurodegenerative disorders, to provide the company’s scientists access to a private R&D marketplace to accelerate their research.

[Read More]

TESARO announces EC approval of ZEJULA for recurrent ovarian cancer

Monday, November 20, 2017

TESARO, an oncology focused biopharmaceutical company, announced that the European Commission (EC) has granted marketing authorization for ZEJULA (niraparib) as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response (CR) or partial response (PR) to platinum-based chemotherapy. ZEJULA is the first once-daily, oral poly (ADP-ribose) polymerase (PARP)1/2 inhibitor to be approved in Europe that does not require BRCAmutation or other biomarker testing.

[Read More]

CrownBio launches grant program to Fund Preclinical Oncology Research

Monday, November 20, 2017

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology.

[Read More]

New Oracle Cloud Infrastructure innovations

Monday, November 20, 2017

Oracle announced the general availability of a range of new Oracle Cloud Infrastructure compute options, providing customers with unparalleled compute performance based on Oracle’s recently announced X7 hardware. Newly enhanced virtual machine (VM) and bare metal compute, and new bare metal graphical processing unit (GPU) instances enable customers to run even the most infrastructure-heavy workloads such as high-performance computing (HPC), big data, and artificial intelligence (AI) faster and more cost-effectively.

[Read More]